Response Genetics, Inc. to Hold Annual Meeting of Stockholders Tuesday, June 16, 2009 at 10:00 am EDT

Business Wire, June 12, 2009

LOS ANGELES -- Response Genetics Inc. (Nasdaq:RGDX) today announced that it will hold its Annual Meeting of stockholders on Tuesday, June 16, 2009, beginning at 10 a.m. EDT at The New York Palace Hotel, 455 Madison Avenue, New York, NY 10022.

The items for consideration at the meeting are included in the Notice of Availability of Proxy Materials, which has been mailed to shareholders of record on April 30, 2009.

Interested parties may access the Annual Meeting via a webcast by visiting the Response Genetics Web site at www.responsegenetics.com. The webcast will be archived on the company’s Web site under “Investor Relations.”

About Response Genetics, Inc.

Response Genetics, Inc. (“RGI”) (the “Company”) (Nasdaq:RGDX) is focused on the development and sale of molecular diagnostic tests for cancer. RGI’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. In addition to diagnostic testing services, RGI generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of RGI related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as the ability of the Company, to analyze cancer samples, the potential for using the results of this research to develop diagnostic tests for cancer, and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions.

These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.